China speed: Data, deals, first-in-class assets — a BioCentury podcast

Dealmaking between Western and Chinese biopharmas has been one of the year’s bright spots, as a maturing biotech landscape in China converges with Western demand for innovative assets, driving record deal flow. At the same time, the Hong Kong stock exchange has emerged as the hottest market for biotech IPOs, at a time when the NASDAQ window remains shut.

These themes — China’s burgeoning biotech innovation, dealmaking strategies, and green shoots in the Hong Kong capital markets — will be in the spotlight at the 12th BioCentury-BayHelix China Healthcare Summit this fall. McKinsey & Company is returning as insights partner for the conference, which runs Oct. 22-24 in Shanghai...